Therefore, the present study aims to compare the efficacy of SGLT2 inhibitors versus GLP-1 receptoragonists in reducing major adverse cardiovascular events (MACE) among patients with T2DM in a real-world clinical setting. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.